Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of OCV-C02 in advanced or relapsed colorectal cancer
jRCT2080222029Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2013
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of OCV-C02 in colorectal cancer (CRC) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of OCV-C02. Started Feb 2013; status: completed.
02
Drugs
OCV-C02
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080222029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222029.